Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Cytophil, Inc.
WARNING LETTER
•Cytophil, Inc.•February 13, 2014

Cytophil, Inc. – FDA Warning Letter, Feb 13, 2014

Record Details

The FDA issued a Warning Letter to Cytophil, Inc. following an inspection from January 27 to February 13, 2014, at their East Troy, Wisconsin facility. The firm manufactures synthetic bone graft material, bone void fillers, and an intranasal splint, classified as devices. The inspection revealed these devices to be adulterated because their manufacturing, packing, storage, or installation methods, facilities, or controls did not conform to the Quality System (QS) regulation (21 CFR Part 820).

Key violations included the failure to adequately establish procedures for controlling environmental conditions (21 CFR 820.70(c)), such as investigating out-of-specification clean room monitoring results and setting temperature/humidity parameters. The firm also failed to adequately validate its sterilization process (21 CFR 820.75(a)), lacking critical parameters like dose mapping and product specifications. Furthermore, Cytophil, Inc. did not adequately establish procedures for changes to specifications (21 CFR 820.70(b)), making changes without verification or validation. Deficiencies were also noted in their corrective and preventive action (CAPA) procedures (21 CFR 820.100(a)), including inadequate investigations and failure to verify corrective action effectiveness. Lastly, the firm lacked adequate process control procedures (21 CFR 820.70(a)) for in-process product temperature and testing, and failed to establish procedures for controlling storage area temperatures (21 CFR 820.150) for sensitive finished devices.

The FDA acknowledged the firm's March 6, 2014 response but stated that corrective actions require verification during a subsequent inspection. Cytophil, Inc. must take prompt action to correct these violations within 15 business days, providing documentation and a timetable. Failure to comply could lead to regulatory actions such as seizure, injunction, civil money penalties, impact on federal contracts, and denial of premarket approvals or Certificates to Foreign Governments. The letter emphasized that these violations might indicate systemic quality management issues requiring thorough investigation.

Company
Cytophil, Inc.
Inspection date
February 13, 2014
Product type
Devices
Office
Minneapolis District Office
People
  • Melissa I. Michurski
  • Michael Dutcher (Acting Assistant Commissioner)
View Company Profile

ID · b6743526-b609-4fda-afac-57008c92711a

Violation Codes9
21 U.S.C. 321(h)21 U.S.C. 351(h)21 CFR 82021 CFR 820.70(c)21 CFR 820.75(a)21 CFR 820.70(b)21 CFR 820.100(a)21 CFR 820.70(a)21 CFR 820.150

Full citation text and observation details available on the Dashboard.

Other documents for Cytophil, Inc.
  • 483 - 2022-07-29July 29, 2022

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Cytophil, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.